Induction of estrogen receptor α-36 expression by bone morphogenetic protein 2 in breast cancer cell lines

Molecular Medicine Reports

Volumn 6, Issue 3, 2012, Pages 591-596

  Wang, Dingding ^a   Huang, Peide ^b   Zhu, Baowei ^b   Sun, Li ^b   Huang, Qing ^b   Wang, Ju ^b  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b National Engineering Research Centre of Genetic Medicine   (China)

Author keywords

Bone morphogenetic protein 2; Breast cancer cell; Estrogen receptor ; Estrogen receptor 36

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; TAMOXIFEN CITRATE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG SENSITIVITY; ESTROGEN RECEPTOR ALPHA 36 GENE; ESTROGEN RECEPTOR ALPHA 66 GENE; GENE EXPRESSION; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; HUMAN CELL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR GENE; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, HORMONAL; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HUMANS; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TAMOXIFEN; UP-REGULATION;

EID: 84865186638     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.945     Document Type: Article

References (30)

1. Miyazono K, Kamiya Y and Morikawa M: Bone morphogenetic protein receptors and signal transduction. J Biochem 147: 35-51, 2010.
2. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM and Wang EA: Novel regulators of bone formation: molecular clones and activities. Science 242: 1528-1534, 1988. (Pubitemid 19023695)
3. Attisano L and Wrana JL: Signal transduction by the TGF-beta superfamily. Science 296: 1646-1647, 2002.
4. Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH, Kotliarova S, Kotliarov Y, Walling J, Ahn S, et al: Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13: 69-80, 2008. (Pubitemid 350309742)
5. Varga AC and Wrana JL: The disparate role of BMP in stem cell biology. Oncogene 24: 5713-5721, 2005. (Pubitemid 43086131)
6. Farnsworth RH, Karnezis T, Shayan R, Matsumoto M, Nowell CJ, Achen MG and Stacker SA: A role for bone morphogenetic protein-4 in lymph node vascular remodeling and primary tumor growth. Cancer Res 71: 6547-6557, 2011.
7. Katzenellenbogen BS and Katzenellenbogen JA: Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2: 335-344, 2000. (Pubitemid 32223616)
8. Glidewell-Kenney C, Weiss J, Lee EJ, Pillai S, Ishikawa T, Ariazi EA and Jameson JL: ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol 245: 53-59, 2005.
9. Holmes KA, Hurtado A, Brown GD, Launchbury R, Ross-Innes CS, Hadfield J, Odom DT and Carroll JS: Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells. Proc Natl Acad Sci USA 109: 2748-2753, 2012.
10. Vasudevan N, Kow LM and Pfaff DW: Early membrane estrogenic effects required for full expression of slower genomic actions in a nerve cell line. Proc Natl Acad Sci USA 98: 12267-12271, 2001. (Pubitemid 32959862)
11. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, et al: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27: 2630-2637, 2009.
12. Edwards DP: Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 67: 335-376, 2005.
13. Liu H, Qiu J, Li N, Chen T, Cao X: Human phosphatidylethanolamine-binding protein 4 promotes transactivation of estrogen receptor alpha (ERalpha) in human cancer cells by inhibiting proteasome-dependent ERalpha degradation via association with Src. J Biol Chem 285: 21934-21942, 2010.
14. Thomas C, Gustafsson JÅ: The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11: 597-608, 2011.
15. Herynk MH and Fuqua SA: Estrogen receptor mutations in human disease. Endocr Rev 25: 869-898, 2004. (Pubitemid 39657771)
16. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y and Deuel TF: Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 336: 1023-1027, 2005. (Pubitemid 41383424)
17. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-1618, 1998.
18. Miller TW, Balko JM and Arteaga CL: Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29: 4452-4461, 2011.
19. Ho CC and Bernard DJ: Bone morphogenetic protein 2 acts via inhibitor of DNA binding proteins to synergistically regulate follicle-stimulating hormone β transcription with activin A. Endocrinology 151: 3445-3453, 2010.
20. ten Dijke P, Korchynskyi O, Valdimarsdottir G and Goumans MJ: Controlling cell fate by bone morphogenetic protein receptors. Mol Cell Endocrinol 211: 105-113, 2003. (Pubitemid 37491242)
21. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y and Deuel TF: A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA 103: 9063-9068, 2006. (Pubitemid 43902533)
22. Lin SL, Yan LY, Zhang XT, et al: ERalpha-36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS One 5: e9013, 2010.
23. Kipp JL, Kilen SM, Woodruff TK and Mayo KE: Activin regulates estrogen receptor gene expression in the mouse ovary. J Biol Chem 282: 36755-36765, 2007.
24. Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Wang Z and Xie Y: Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 27: 3423-3429, 2009.
25. Lee LM, Cao J, Deng H, Chen P, Gatalica Z and Wang ZY: ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res 28: 479-483, 2008.
26. Wu L, Wu Y, Gathings B, Wan M, Li X, Grizzle W, Liu Z, Lu C, Mao Z and Cao X: Smad4 as a transcription corepressor for estrogen receptor alpha. J Biol Chem 278: 15192-15200, 2003. (Pubitemid 36799854)
27. Matsumoto Y, Otsuka F, Takano M, Mukai T, Yamanaka R, Takeda M, Miyoshi T, Inagaki K, Sada KE and Makino H: Estrogen and glucocorticoid regulate osteoblast differentiation through the interaction of bone morphogenetic protein-2 and tumor necrosis factor-alpha in C2C12 cells. Mol Cell Endocrinol 325: 118-127, 2010.
28. Oreffo RO, Kusec V, Romberg S and Triffitt JT: Human bone marrow osteoprogenitors express estrogen receptor-alpha and bone morphogenetic proteins 2 and 4 mRNA during osteoblastic differentiation. J Cell Biochem 75: 382-392, 1999. (Pubitemid 29521647)
29. Zhang M, Wang Q, Yuan W, Yang S, Wang X, Yan JD, Du J, Yin J, Gao SY, Sun BC and Zhu TH: Epigenetic regulation of bone morphogenetic protein-6 gene expression in breast cancer cells. J Steroid Biochem Mol Biol 105: 91-97, 2007. (Pubitemid 47211944)
30. Yamamoto T, Saatcioglu F and Matsuda T: Cross-talk between bone morphogenic proteins and estrogen receptor signaling. Endocrinology 143: 2635-2642, 2002. (Pubitemid 34701327)